Thursday, October 15, 2020 1:20:20 PM
All eggs in the 102 patient review and not even talk of completing the first part of the IV 2B Trial, and nothing on amount of patients needed to reach statistical significance with the Phase 3 part. Seeing the last FDA update on approvals seems to show Full Data is King/Queen/Game or dont apply, IMO. Huge amount of 'Hope' for FDA EUA, general approvals on the 102. Guess Dr JJ/NRX feels no need for further plans. Kept pushing the 21 data. One of the slides on today's presentation showed a P<=.0001, so how much more certainty do they need for EUA? By the time we get EUA, I think there will be more discussion about full FDA approval. Also, there is more data they have on the open label trial.
EOD volume at SIX/here ? anyone have an opinion besides me. Price after this news. Creep up some, creep down some until EAU or full FDA approval
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM